Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
8.97 USD | -0.44% | +0.11% | -20.20% |
Mar. 01 | Tranche Update on Theravance Biopharma, Inc.'s Equity Buyback Plan announced on September 19, 2022. | CI |
Feb. 26 | Transcript : Theravance Biopharma, Inc., Q4 2023 Earnings Call, Feb 26, 2024 |
Financials (USD)
Sales 2024 * | 73M | Sales 2025 * | 97.03M | Capitalization | 432M |
---|---|---|---|---|---|
Net income 2024 * | -31M | Net income 2025 * | -16M | EV / Sales 2024 * | 5.92 x |
Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | 4.45 x |
P/E ratio 2024 * |
-13.9
x | P/E ratio 2025 * |
-27.5
x | Employees | 99 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 94.84% |
Latest transcript on Theravance Biopharma, Inc.
1 day | -0.44% | ||
1 week | +0.11% | ||
Current month | -5.28% | ||
1 month | -4.57% | ||
3 months | -20.69% | ||
6 months | +7.04% | ||
Current year | -20.20% |
Managers | Title | Age | Since |
---|---|---|---|
Rick Winningham
CEO | Chief Executive Officer | 64 | 13-06-30 |
Aziz Sawaf
DFI | Director of Finance/CFO | 42 | 14-05-31 |
Stuart Knight
CTO | Chief Tech/Sci/R&D Officer | - | 14-10-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Dean Mitchell
BRD | Director/Board Member | 68 | 14-05-31 |
Eran Broshy
BRD | Director/Board Member | 65 | 14-06-01 |
Burt Malkiel
BRD | Director/Board Member | 90 | 13-09-30 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.06% | 0 M€ | 0.00% | - | |
0.06% | 0 M€ | 0.00% | - | |
0.03% | 735 M€ | -.--% | - | |
0.02% | 464 M€ | -.--% |
Date | Price | Change | Volume |
---|---|---|---|
24-03-28 | 8.97 | -0.44% | 401,710 |
24-03-27 | 9.01 | +2.15% | 320,008 |
24-03-26 | 8.82 | +0.68% | 296,175 |
24-03-25 | 8.76 | -1.79% | 365,382 |
24-03-22 | 8.92 | -0.45% | 303,569 |
Delayed Quote Nasdaq, March 28, 2024 at 04:30 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-20.20% | 432M | |
+33.46% | 701B | |
+26.24% | 570B | |
+0.93% | 381B | |
+21.03% | 334B | |
+17.51% | 322B | |
+0.74% | 209B | |
+2.95% | 212B | |
-6.05% | 205B | |
-3.61% | 157B |